Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UNLABELLED: Screening for a condition should only be undertaken if certain strict criteria are met. Congenital CMV (cCMV) is a leading cause of sensorineuronal hearing loss (SNHL) and meets many of these criteria, but is not currently screened for in the UK. Ganciclovir reduces CMV-induced progressive SNHL if treatment is begun in the first month of life. The Newborn Hearing Screening Programme (NHSP) has been shown to identify SNHL at the earliest possible age. The potential of integrating screening for cCMV into the NHSP is discussed to consolidate the link between screening, early diagnosis and management. CONCLUSION: The early diagnosis and treatment of cCMV may prevent a small proportion of late SNHL. In the absence of any screening programme, we provide evidence that clinically targeted screening through the NHSP is a potential option in the UK, enhancing the diagnostic pathway and enabling appropriate early treatment to reduce long-term morbidity.

Original publication

DOI

10.1111/apa.12335

Type

Journal article

Journal

Acta Paediatr

Publication Date

10/2013

Volume

102

Pages

928 - 933

Keywords

Congenital CMV, Screening, Sensorineural hearing loss, Antiviral Agents, Cytomegalovirus Infections, Early Diagnosis, Feasibility Studies, Ganciclovir, Hearing Loss, Sensorineural, Humans, Infant, Newborn, Neonatal Screening, State Medicine, United Kingdom